LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Затворен

1.55 0.65

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.54

Максимум

1.56

Ключови измерители
By Trading Economics
Приходи	17M -26M
EPS	-0.43
Марж на печалбата	-2,190.837
Служители	171
EBITDA	19M -23M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+92.31% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-1.1M 101M
Предишно отваряне	0.9
Предишно затваряне	1.55

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

21.11.2025 г., 22:42 ч. UTC

Пазарно говорене

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

21.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

21.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

21.11.2025 г., 21:47 ч. UTC

Пазарно говорене

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

21.11.2025 г., 21:43 ч. UTC

Пазарно говорене

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

21.11.2025 г., 20:18 ч. UTC

Пазарно говорене

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

21.11.2025 г., 20:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

21.11.2025 г., 19:48 ч. UTC

Пазарно говорене

Precious Metals Fall for the Week -- Market Talk

21.11.2025 г., 19:44 ч. UTC

Печалби

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

21.11.2025 г., 19:37 ч. UTC

Пазарно говорене

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

21.11.2025 г., 19:27 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

21.11.2025 г., 19:27 ч. UTC

Пазарно говорене

Печалби

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

21.11.2025 г., 19:20 ч. UTC

Пазарно говорене

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

21.11.2025 г., 18:44 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

21.11.2025 г., 18:37 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

21.11.2025 г., 18:34 ч. UTC

Пазарно говорене

Печалби

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

21.11.2025 г., 18:28 ч. UTC

Печалби

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21.11.2025 г., 18:03 ч. UTC

Пазарно говорене

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

21.11.2025 г., 17:24 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

21.11.2025 г., 17:24 ч. UTC

Пазарно говорене

Intuit Seen on Path to Increase Growth -- Market Talk

21.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

21.11.2025 г., 17:05 ч. UTC

Пазарно говорене

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

21.11.2025 г., 16:56 ч. UTC

Пазарно говорене

Gold Recovers as Investors Boost Rate-Cut Bets -- Market Talk

21.11.2025 г., 16:47 ч. UTC

Пазарно говорене

European Gas-Price Forecast to Decline Further on Expanding LNG Supply -- Market Talk

21.11.2025 г., 16:35 ч. UTC

Придобивния, сливания и поглъщания

What Stocks Al Gore's Investment Firm Bought and Sold This Quarter -- Barrons.com

21.11.2025 г., 16:09 ч. UTC

Печалби

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21.11.2025 г., 15:59 ч. UTC

Пазарно говорене

Canadian Consumers Tapping the Brakes, Still See Resilient -- Market Talk

21.11.2025 г., 15:59 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

21.11.2025 г., 15:23 ч. UTC

Пазарно говорене

Bank of Canada Not Expected to Be Swayed by Canadian Retail Trade Data -- Market Talk

21.11.2025 г., 15:17 ч. UTC

Пазарно говорене

Canadian Consumer Spending Softening, But Could Be Worse -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

92.31% нагоре

12-месечна прогноза

Среден 3 USD 92.31%

Висок 4 USD

Нисък 2 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.